A Safety Study of PTI-125 in Healthy Volunteers
Sponsor
Pain Therapeutics (Industry)
Overall Status
Completed
CT.gov ID
NCT03784300
Collaborator
National Institute on Aging (NIA) (NIH)
24
1
6
7.3
3.3
Study Details
Study Description
Brief Summary
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This was a Phase I, single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy volunteers, 18 to 45 years of age. A total of twenty-four (24) subjects were enrolled into the study in one of three dose cohorts. Each cohort contained eight subjects; six subjects received PTI-125 and two received placebo. Three doses of PTI-125 oral solution (50, 100, and 200 mg) or placebo solution were administered to respective cohorts.
The study included a screening period (Day -28 to Day -1), an inpatient treatment period (Day 0 through Day 4), and a follow-up visit (Day 7). Subjects reported to the clinic on the day before dosing and were randomized to receive either a single dose of orally administered PTI-125 or placebo. Each dose was administered following an overnight fast of at least 10 hours.
For each dose level, dosing was staggered such that two subjects (one active and one placebo) were dosed prior to the rest of the group. After a minimum of 24 hours and review of all 24-hour safety assessments (electrocardiogram [ECG], a brief physical examination, vital signs, and laboratory assessments) an independent Data Safety Monitoring Board/Data Monitoring Committee (DSMB/DMC) determined whether the remaining 6 subjects were to be dosed.
Pharmacokinetic blood samples were obtained prior to dosing and at specified intervals during the study (0-72 hours post-dose). Blood draws for laboratory testing were performed prior to dosing and at 24 hours post dose. After safety assessments of ECG, vital signs, and a brief physical exam at 72 hours, subjects were discharged from the clinic and returned 7 days post-dose for a final safety assessment.
Study Design
Study Type:
Interventional
Actual Enrollment
:
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
Actual Study Start Date
:
Aug 18, 2017
Actual Primary Completion Date
:
Oct 9, 2017
Actual Study Completion Date
:
Mar 27, 2018
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: 50 mg PTI-125 Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. |
Drug: 50 mg PTI-125
PTI-125 50 mg Oral Solution
|
| Placebo Comparator: 50 mg PTI-125 Placebo Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. |
Drug: 50 mg PTI-125
PTI-125 50 mg Oral Solution
|
| Active Comparator: 100 mg PTI-125 Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. |
Drug: 100 mg PTI-125
PTI-125 100 mg Oral Solution
|
| Placebo Comparator: 100 mg PTI-125 Placebo Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. |
Drug: 100 mg PTI-125
PTI-125 100 mg Oral Solution
|
| Active Comparator: 200 mg PTI-125 Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. |
Drug: 200 mg PTI-125
PTI-125 200 mg Oral Solution
|
| Placebo Comparator: 200 mg PTI-125 Placebo Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. |
Drug: 200 mg PTI-125
PTI-125 200 mg Oral Solution
|
Outcome Measures
Primary Outcome Measures
- Maximum Plasma Concentration (Cmax) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The peak drug concentration will be obtained directly from the data without interpolation.
- Time to Maximum Plasma Concentration (Tmax) (Tmax) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The time to peak drug concentration will be obtained directly from the data without interpolation
- Time to Last Quantifiable Plasma Concentration (Tlast) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.
- Last Quantifiable Plasma Concentration (Clast) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration
- Elimination Rate Constant (λz) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The elimination rate constant (λz) will be calculated.
- Termination Elimination Half-Life (T1/2) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The terminal elimination half-life (T1/2) will be calculated.
- Area Under the Curve (AUC) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.
- Area Under the Curve to Infinity (AUCinf) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.
- Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]). [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The percentage of AUCinf based on extrapolation (AUCextrap[%]).
- Oral Clearance (Cl/F) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
The apparent oral clearance will be calculated.
- Volume of Distribution (Vz/F) [Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.]
Vz/F, apparent volume of distribution will be calculated.
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Male or female subjects between 18 and 45 years of age, inclusive.
-
The subject has a body mass index (BMI) within 18-30 kg/m2 (inclusive).
-
The subject is in good health as determined by medical history and physical examination and clinical laboratory parameters.
-
The subject is willing and able to speak, read, and understand English and provide written informed consent.
-
The subject is a non-smoker for at least 12 months. If a former smoker, the reason for stopping must be evaluated.
-
Females who are physically incapable of childbearing defined as postmenopausal, or surgically sterile (hysterectomy, bilateral tubal ligation, bilateral oophorectomy or an Essure procedure). Appropriate documentation (ex; medical record) of the surgical sterilization procedure to be obtained and held within the subject's study file.
-
The subject must agree to comply with the drawing of blood samples for the PK assessments.
-
The subject is willing and able to comply with all testing and requirements defined in the protocol.
-
The subject is willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit.
Exclusion Criteria:
-
The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator.
-
The subject has had a clinically significant illness within 30 days of Check-in.
-
The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
-
The subject has used any prescription medication within 14 days of dosing or overthe- counter (OTC) medication within 48 h of dosing or intends to use any prescription medication or OTC medication during the study that may interfere with the evaluation of study medication.
-
The subject has used alcohol, caffeine or xanthine-containing products 48 h before dosing or intends to use any of these products during the study.
-
The subject has used grapefruit, grapefruit juice, or grapefruit-containing products days before dosing or intends to use any of these products during the study.
-
The subject has a history of substance abuse or a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in. The subject has a positive serum hepatitis B surface antigen or positive HCV antibody test at the Screening Visit.
-
The subject has a positive HIV test at the Screening Visit.
-
Female subject is pregnant or breastfeeding.
-
The subject has received an investigational drug within 30 days of Check-in.
-
The subject has donated or lost a significant volume of blood (>450 mL) within 4 weeks prior to the study.
-
The subject is unwilling to reside in the study unit for the duration of the study or to cooperate fully with the investigator or site personnel.
-
The subject has an AST/ALT or total bilirubin greater than the ULN. One repeat test will be allowed.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Worldwide Clinical Trials | San Antonio | Texas | United States | 78217 |
Sponsors and Collaborators
- Pain Therapeutics
- National Institute on Aging (NIA)
Investigators
- Principal Investigator: George J Atiee, MD, Worldwide Clinical Trials
Study Documents (Full-Text)
More Information
Publications
None provided.Responsible Party:
Pain Therapeutics
ClinicalTrials.gov Identifier:
NCT03784300
Other Study ID Numbers:
- PTI-125-01
- 1R44AG056166
First Posted:
Dec 21, 2018
Last Update Posted:
May 10, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Period Title: Overall Study | ||||||
| STARTED | 6 | 2 | 6 | 2 | 6 | 2 |
| COMPLETED | 6 | 2 | 6 | 2 | 6 | 2 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo | Total |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Total of all reporting groups |
| Overall Participants | 6 | 2 | 6 | 2 | 6 | 2 | 24 |
| Age (Count of Participants) | |||||||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
6
100%
|
2
100%
|
6
100%
|
2
100%
|
6
100%
|
2
100%
|
24
100%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Age (Years) [Mean (Full Range) ] | |||||||
| Mean (Full Range) [Years] |
38.2
|
31.8
|
35.3
|
31.8
|
35.8
|
31.8
|
35.3
|
| Sex: Female, Male (Count of Participants) | |||||||
| Female |
2
33.3%
|
0
0%
|
1
16.7%
|
0
0%
|
1
16.7%
|
0
0%
|
4
16.7%
|
| Male |
4
66.7%
|
2
100%
|
5
83.3%
|
2
100%
|
5
83.3%
|
2
100%
|
20
83.3%
|
| Race (NIH/OMB) (Count of Participants) | |||||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
3
50%
|
1
50%
|
4
66.7%
|
2
100%
|
2
33.3%
|
1
50%
|
13
54.2%
|
| White |
3
50%
|
1
50%
|
2
33.3%
|
0
0%
|
4
66.7%
|
1
50%
|
11
45.8%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Region of Enrollment (Count of Participants) | |||||||
| United States |
6
100%
|
2
100%
|
6
100%
|
2
100%
|
6
100%
|
2
100%
|
24
100%
|
Outcome Measures
| Title | Maximum Plasma Concentration (Cmax) |
|---|---|
| Description | The peak drug concentration will be obtained directly from the data without interpolation. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [ng/mL] |
315
(96.6)
|
NA
(NA)
|
550
(146)
|
NA
(NA)
|
1240
(276)
|
NA
(NA)
|
| Title | Time to Maximum Plasma Concentration (Tmax) (Tmax) |
|---|---|
| Description | The time to peak drug concentration will be obtained directly from the data without interpolation |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [hours] |
1.56
(0.69)
|
NA
(NA)
|
1.08
(0.48)
|
NA
(NA)
|
1.28
(0.57)
|
NA
(NA)
|
| Title | Time to Last Quantifiable Plasma Concentration (Tlast) |
|---|---|
| Description | The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [hours] |
44.0
(16.4)
|
NA
(NA)
|
46.0
(4.6)
|
NA
(NA)
|
50.00
(11.8)
|
NA
(NA)
|
| Title | Last Quantifiable Plasma Concentration (Clast) |
|---|---|
| Description | The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [ng/mL] |
1.04
(0.495)
|
NA
(NA)
|
0.795
(0.294)
|
NA
(NA)
|
0.806
(0.292)
|
NA
(NA)
|
| Title | Elimination Rate Constant (λz) |
|---|---|
| Description | The elimination rate constant (λz) will be calculated. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [1/hour] |
0.141
(0.0539)
|
NA
(NA)
|
0.157
(0.0155)
|
NA
(NA)
|
0.144
(0.0516)
|
NA
(NA)
|
| Title | Termination Elimination Half-Life (T1/2) |
|---|---|
| Description | The terminal elimination half-life (T1/2) will be calculated. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [hours] |
6.05
(3.87)
|
NA
(NA)
|
4.45
(0.39)
|
NA
(NA)
|
5.93
(3.87)
|
NA
(NA)
|
| Title | Area Under the Curve (AUC) |
|---|---|
| Description | The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [h*ng/mL] |
2040
(893)
|
NA
(NA)
|
3130
(1150)
|
NA
(NA)
|
8130
(1530)
|
NA
(NA)
|
| Title | Area Under the Curve to Infinity (AUCinf) |
|---|---|
| Description | The AUC from time zero extrapolated to infinity (AUCinf) will be calculate. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [h*ng/mL] |
2180
(897)
|
NA
(NA)
|
3260
(1150)
|
NA
(NA)
|
8250
(1530)
|
NA
(NA)
|
| Title | Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]). |
|---|---|
| Description | The percentage of AUCinf based on extrapolation (AUCextrap[%]). |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [percent extrapolated] |
0.410
(0.187)
|
NA
(NA)
|
0.151
(0.0366)
|
NA
(NA)
|
0.144
(0.0156)
|
NA
(NA)
|
| Title | Oral Clearance (Cl/F) |
|---|---|
| Description | The apparent oral clearance will be calculated. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [(L/h)] |
25.7
(8.42)
|
NA
(NA)
|
33.0
(8.16)
|
NA
(NA)
|
24.9
(4.53)
|
NA
(NA)
|
| Title | Volume of Distribution (Vz/F) |
|---|---|
| Description | Vz/F, apparent volume of distribution will be calculated. |
| Time Frame | Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort. |
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo |
|---|---|---|---|---|---|---|
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution |
| Measure Participants | 6 | 2 | 6 | 2 | 6 | 2 |
| Mean (Standard Deviation) [(L)] |
199
(64.9)
|
NA
(NA)
|
215
(64.8)
|
NA
(NA)
|
214
(154)
|
NA
(NA)
|
Adverse Events
| Time Frame | 7 days | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||||
| Arm/Group Title | 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo | ||||||
| Arm/Group Description | Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort. 50 mg PTI-125: PTI-125 50 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort. 100 mg PTI-125: PTI-125 100 mg Oral Solution | Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort. 200 mg PTI-125: PTI-125 200 mg Oral Solution | ||||||
All Cause Mortality |
||||||||||||
| 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/6 (0%) | 0/2 (0%) | 0/6 (0%) | 0/2 (0%) | 0/6 (0%) | 0/2 (0%) | ||||||
Serious Adverse Events |
||||||||||||
| 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/6 (0%) | 0/2 (0%) | 0/6 (0%) | 0/2 (0%) | 0/6 (0%) | 0/2 (0%) | ||||||
Other (Not Including Serious) Adverse Events |
||||||||||||
| 50 mg PTI-125 | 50 mg PTI-125 Placebo | 100 mg PTI-125 | 100 mg PTI-125 Placebo | 200 mg PTI-125 | 200 mg PTI-125 Placebo | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/6 (0%) | 0/2 (0%) | 1/6 (16.7%) | 0/2 (0%) | 1/6 (16.7%) | 0/2 (0%) | ||||||
| Musculoskeletal and connective tissue disorders | ||||||||||||
| transient musculoskeletal wall pain | 0/6 (0%) | 0 | 0/2 (0%) | 0 | 0/6 (0%) | 0 | 0/2 (0%) | 0 | 1/6 (16.7%) | 1 | 0/2 (0%) | 0 |
| Nervous system disorders | ||||||||||||
| lightheadedness | 0/6 (0%) | 0 | 0/2 (0%) | 0 | 1/6 (16.7%) | 1 | 0/2 (0%) | 0 | 0/6 (0%) | 0 | 0/2 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||||||||||
| Acne | 0/6 (0%) | 0 | 0/2 (0%) | 0 | 0/6 (0%) | 0 | 0/2 (0%) | 0 | 1/6 (16.7%) | 1 | 0/2 (0%) | 0 |
Limitations/Caveats
[Not Specified]
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Michael R Marsman, PharmD |
|---|---|
| Organization | Cassava Sciences |
| Phone | 5125822173 |
| mmarsman@cassavasciences.com |
Responsible Party:
Pain Therapeutics
ClinicalTrials.gov Identifier:
NCT03784300
Other Study ID Numbers:
- PTI-125-01
- 1R44AG056166
First Posted:
Dec 21, 2018
Last Update Posted:
May 10, 2021
Last Verified:
May 1, 2021